Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Response To ESA "Overuse" In CKD Will Await Impact Of Bundled Payments, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Final CMS decision confirms proposal to withhold a national Medicare coverage policy for erythropoiesis stimulating agents in chronic kidney disease.
Advertisement

Related Content

Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease
CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease
ESA REMS Allows Oncologists A Year To Enroll In Patient Education Program

Topics

Advertisement
UsernamePublicRestriction

Register

PS072381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel